Study Status: Active, not recruiting
Recruit Status: Active, not recruiting
Study Type: Interventional
Official Title: A PHASE II EVALUATION OF DALANTERCEPT, A NOVEL SOLUBLE RECOMBINANT ACTIVIN RECEPTOR-LIKE KINASE 1 (ALK-1) INHIBITOR RECEPTOR-FUSION PROTEIN, IN THE TREATMENT OF RECURRENT OR PERSISTENT ENDOMETRIAL CAR
Brief Summary: This phase II trial studies how well dalantercept works in treating patients with recurrent or persistent endometrial cancer. Dalantercept may stop the growth of endometrial cancer by blocking blood flow to the tumor.